Page last updated: 2024-12-08
gp 531
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
GP 531: an adenosine-regulating agent; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 164444 |
| SCHEMBL ID | 4885021 |
| MeSH ID | M0269942 |
Synonyms (18)
| Synonym |
|---|
| gp 531 |
| 142344-87-4 |
| 5-amino-1-[(2r,3r,4s,5r)-5-[(benzylamino)methyl]-3,4-dihydroxyoxolan-2-yl]imidazole-4-carboxamide |
| gp-531 |
| 5-amino-1-beta-d-(5'-benzylamino-5'-deoxyribofuranosyl)imidazole-4-carboxamide |
| 1h-imidazole-4-carboxamide, 5-amino-1-(5-deoxy-5-((phenylmethyl)amino)-beta-d-ribofuranosyl)- |
| uk37hm0cdg , |
| unii-uk37hm0cdg |
| SCHEMBL4885021 |
| CS-7153 |
| gp531 |
| HY-U00116 |
| 5-amino-1-(5-deoxy-5-((phenylmethyl)amino)-.beta.-d-ribofuranosyl)-1h-imidazole-4-carboxamide |
| 1h-imidazole-4-carboxamide, 5-amino-1-(5-deoxy-5-((phenylmethyl)amino)-.beta.-d-ribofuranosyl)- |
| DTXSID90931415 |
| 5-amino-1-[5-(benzylamino)-5-deoxypentofuranosyl]-1h-imidazole-4-carboximidic acid |
| MS-25342 |
| AKOS040740801 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (60.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 21.67
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (21.67) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||